Acutus Medical Inc.
Latest From Acutus Medical Inc.
The deal includes $100m in Series D financing and a $70m credit facility to help Acutus market the AcQMap electrophysiology mapping system along with the associated vascular access devices, AcQCross QX, AcQGuide Flex and AcQGuide Mini.
Acutus announced a deal to acquire Rhythm Xience, and new strategic partnerships with Peerbridge Health, Cardiac Designs and MedFact, to offer more electrophysiology products that complement its AcQMap multi-electrode electrophysiology mapping catheter system.
New trial results show Acutus Medical's AcQMap platform has the ability to classify conduction patterns and localized non-pulmonary-vein therapeutic targets for ablation to treat atrial fibrillation, which could have implications for both treatment of atrial fibrillation and understanding the genetic markers for this common arrhythmia, according to the authors.
Starts & Stops: CardioFocus Studies HeartLight X3 In Persistent AF; IntraLink Spine Launches Trial Of Low-Back Device In Australia
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by Meddevicetracker. This edition covers trial announcements from March 4 through March 17, including trial announcements from CardioFocus, Innovative Cardiovascular Solutions, IntraLink-Spine, Geneveve, Acutus, and Stereotaxis.
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Acutus Medical Inc.
- Senior Management
Vince Burgess, Chmn., Pres. & CEO
Gary W Doherty, CFO
Mike Iversen, Chief Commercial Officer
Steven McQuillan, SVP, Regulatory & Clinical Affairs
Peter Elia, Head, Bus. & Mkt. Dev.
Tim Corvi, VP, R&D
- Contact Info
Acutus Medical Inc.
Phone: (442) 232-6080
2210 Faraday Ave., Ste. 100
Carlsbad, CA 92008
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.